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SUMMARY. The incidence of esophageal adenocarcinoma (EAC) has increased in recent decades. Increases in
incidence have been attributed to changes in the prevalence of risk factors for EAC; however, the extent to which
these changes explain increases in EAC incidence has not been studied in detail. We used age-period-cohort analysis
to estimate changes in the incidence of EAC among white males by age, time period, and birth cohort. Incidence
rates per 100,000 individuals were analyzed from 1973 to 2012. Hierarchical Poisson models were used to esti-
mate age, period, and cohort effects, whereby age-specific incidence rates were nested within periods and cohorts.
The prevalence of obesity for each time period and birth cohort was included in the model as a fixed-effect. Incidence
increased with advancing age (β = 0.12, P < 0.01). There were significant period and birth cohort effects, although
the period effect was much larger than the cohort effect. The period effect decreased dramatically when obesity was
included as a fixed effect, while the small cohort effect remained unchanged. Results suggest much of the increase in
the incidence of EAC can be attributed to a period effect, which may be due to changes in the prevalence of obesity
over time.
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INTRODUCTION
The incidence of esophageal adenocarcinoma (EAC)
has rapidly increased since the 1970s,1–4 with annual
increases of up to 8% between 1973 and 1996 and 2%
since 1996.5 Changes in the incidence patterns of EAC
have been largely attributed to changes in the preva-
lence of risk factors. Obesity and gastroesophageal
reflux disease (GERD), both well-established risk fac-
tors of EAC,6,7 have increased since the 1970s.8,9
More than one-third of persons living in the U.S.
are obese,8 while the prevalence of GERD symptoms
(e.g. heartburn, acid reflux) has more than doubled
in the last 20 years.9 Both the increases in obesity
and GERD coincide with the rise in EAC. Although
the increase in EAC has slowed in recent years,5,10 it
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remains one of the few cancers in the U.S. with a rising
incidence.11
Although changes in risk factors across time have
been extensively documented, the extent to which
these changes explain increases in the incidence of
EAC is poorly understood. Further, relatively little
attention has been given to cohort effects (i.e. changes
across groups of individuals who experience events
at the same age during any given time period).
Because birth cohorts often have different expo-
sures to behavioral and environmental risk factors,
cohort effects are evident in many cancers and chronic
diseases.12 Cohort effects are distinct from period
effects, which represent variations over time periods
that influence all age groups simultaneously.12 Several
studies have analyzed secular trends in EAC incidence
rates,2,3,5,10,13–15 but by comparison, few have quanti-
fied period or cohort effects.
We used age-period-cohort (APC) analysis to esti-
mate changes in the incidence of EAC among white
males by age, period, and cohort. APC analysis,
C© 2017 International Society for Diseases of the Esophagus 1
2 Diseases of the Esophagus
widely used in sociology and demography research,
combines information on respondent age, time period
of observation, and birth cohort to track the preva-
lence of a health outcome over time.12 These models
estimate independent age effects (i.e. distribution of
the outcome across the life course due to the bio-
logical process of aging), period effects (i.e. secular
trends in the prevalence of an outcome that occur in
all ages), and cohort effects (i.e. variation in the out-
come among those born in or around the same year).
The purpose of this studywas to (1) estimate the dif-
ferential contributions of age, period, and birth cohort
to the increasing incidence of EAC, and (2) determine
how changes in the prevalence of obesity account for
incidence patterns by period and cohort.
MATERIALS ANDMETHODS
EAC incidence
Incidence of EAC among white males was derived
from the National Cancer Institute’s (NCI) Surveil-
lance, Epidemiology, and End Results (SEER) pro-
gram. We limited the study population to white
males because EAC is far more common among men
than women (4.8 per 100,000 vs. 0.6 per 100,000)
and whites than blacks (2.6 per 100,000 vs. 0.6
per 100,000). SEER 9 registries include Atlanta,
Connecticut, Detroit, Hawaii, Iowa, New Mexico,
San Francisco—Oakland, Seattle—Puget Sound, and
Utah, approximately 9.5% of the U.S. population.
Incidence rates per 100,000 individuals within the
population were analyzed from 1973 to 2012. EAC
was defined anatomically as located in the esophagus
(International Classification of Disease for Oncology,
Third Edition [ICD-O-3] codes 150-159) and histolog-
ically as adenocarcinoma (ICD-O-3 codes 8140-8141,
8143-8145, 8190-8231, 8260-8263, 8310, 8401, 8480-
8490, 8550-8551, 8570-8574, 8576).
Obesity prevalence
Obesity prevalence was determined using data from
the National Health and Nutrition Examination
Survey (NHANES), phases I (1971–1975), II (1976–
1980), and III (1988–1994) and the continuous cycles
(1999–2012). NHANES is the only study that pro-
vides estimates on anthropometric measures for the
U.S. population. The survey examines a nationally
representative sample of about 5,000 persons each
year. These persons are located in counties across the
country, 15 of which are visited in each data collec-
tion cycle. Data collection procedures include a stan-
dardized physical examination, where a trained health
technologist and recorder work together to collect a
complete set of anthropometric measures (e.g. weight,
height, upper leg and arm length) from survey par-
ticipants. Obesity is measured as a body mass index
(BMI) ≥30 kg/m2.
To estimate the prevalence of period-specific obe-
sity, we pooled obesity prevalence across all age
groups for white males (age≥21 years) during the cor-
respondingNHANES periods of data collection. Sim-
ilarly, we estimated the prevalence of cohort-specific
obesity by averaging obesity prevalence for white
males (age ≥21 years) in each birth cohort across
the same NHANES time periods. Because NHANES
studies were not conducted in certain years (e.g. 1981–
1987), we interpolated obesity prevalence by aver-
aging the prevalence for the previous and subsequent
periods or cohorts. To account for the possibility
that EAC incidence increases linearly with BMI (vs.
a threshold effect of BMI ≥30), we also estimated
period- and cohort-specific mean and median BMI
using a similar approach.
Statistical analysis
Age, period, and cohort effects can be estimated with
a variety of statistical techniques. We used hierar-
chical Poisson models to nest age-specific incidence
rates within levels of period and birth cohort. Specif-
ically, the models estimate fixed effects of age and
random effects of period and birth cohort.12 Hierar-
chical APC analysis avoids the identification problem
of linear APC regression models because age, period,
and cohort are not assumed to be linear and additive
at the same level of analysis. These models enhance
the ability to assess the independent effect of each
by estimating variance components. Variance compo-
nents are interpreted as the period or cohort effect.
The effect of each cohort is averaged over all periods,
and the contribution of each period is averaged over
all cohorts. Model components and parameters are
defined in detail as Supporting Information.
Hierarchical APCmodels also provide a framework
to incorporate covariates that may explain period
and/or cohort effects. To determine the extent to
which obesity accounts for the observed variance by
period and cohort, we included in the model the
prevalence of period- and cohort-specific obesity as
covariates with fixed effects. A change in the variance
components (in both size and statistical significance)
provides evidence for a period and/or cohort effect
attributable to obesity. We also specified models with
period- and cohort- specific mean and median BMI
to account for the possibility that incidence of EAC
increases linearly with BMI (vs. a threshold effect
of BMI ≥30). Lastly, we developed anthropometry-
lagged models that included a lag period of 5, 10, and
15 years between period-obesity and incidence rates.
Cohort and period were divided into approximate
5-year categories for 21 birth cohorts (1885–1991)
and 9 time periods (1973–2012). Continuous age
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Fig. 1 Estimates of fixed level covariates: obesity prevalence by time period, 1973–2010; B) Mean and median BMI by time period, 1973–
2012; C) Obesity prevalence by birth cohort, 1885–1991; D)Mean andmedian BMI by birth cohort, 1885–1991. Period– and cohort–obesity
were dervied fromNHANES phases I (1971–1975), II (1976–1980), and III (1988–1994) and the continuous cycles (1999–2012). All estimates
were calculated with sampling weights that account for nonresponse and oversampling in NHANES.
(21–85+ years) was centered at the mean to facili-
tate interpretation of the random effects and reduce
the association between the linear and quadratic age
terms.
All statistical analyses were conducted using SAS
version 9.3 (SAS Institute, Cary, North Carolina,
USA).
RESULTS
Period-obesity ranged from 12.1% (1973–1974, 1975–
1979) to 40.3% (2010–2012), and cohort-obesity
ranged from 10.0% (1885–1890) to 36.8% (1985–1991)
(Fig. 1).
Age-period incidence rates are shown in Figure 2.
Incidence rates generally increased from age 40
through 70 and slightly decreased in the oldest age
groups (≥80 years). Incidence rates for all age groups
were relatively low through the early 1980s, with
marked increases starting in 1990. Age-birth cohort
incidence rates (Fig. 3) increased across successive
birth cohorts for older age groups (≥60 years) but
Fig. 2 Age by time period incidence rates of esophageal adeno-
carcinoma for white males, SEER 9, 1973-2012. Note: In the above
figure, age (in years) is along the x-axis, and each line represents inci-
dence rates across age during an approximate 5-year time period.
Incidence of EAC increased with advancing age, and rates were
highest in more recent time periods (e.g. 2010–2012).
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Fig. 3 Birth cohort by age incidence rates of esophageal adeno-
carcinoma for white males, SEER 9, 1973–2012. Note: In the above
figure, birth cohort is along the x-axis, and each line represents inci-
dence rates across birth cohort for approximate 5-year age groups.
Incidence of EAC increased across successive birth cohorts for older
age groups (>=60 years) but remained low among the youngest age
groups.
Fig. 4 Birth cohort by time period incidence rates of esophageal
adenocarcinoma for white males, SEER 9, 1973–2012. Note: In the
above figure, birth cohort is along the x-axis, and each line rep-
resents incidence rates across birth cohort for approximate 5-year
time periods. Incidence of EAC increased across the 1900-1930 birth
cohorts and decreased successively acrossmore recent birth cohorts.
remained low among the youngest age groups. Period-
birth cohort incidence (Fig. 4) increased across the
1900–1930 birth cohorts and decreased successively
across more recent birth cohorts.
Results of the hierarchical APC analysis (Table 1,
Model A) demonstrate significant age effects
(β = 0.116, P< 0.001). Incidence rates increased with
increasing age and decreased slightly in the oldest
ages (β =−0.002, P< 0.001). For example, predicted
incidence at age 80 years across all periods and
cohorts was 15.3/100,000 (95% confidence interval
[CI]: 9.5/100,000, 24.6/100,000) and 14.3/100,000
(95% CI: 8.9/100,000, 23.0/100,000) at age 85 years.
There was also a period effect (σ = 0.498, P= 0.025),
suggesting, independent of both age and birth cohort,
incidence rates increased monotonically over time.
The observed cohort effect (σ = 0.027, P = 0.046)
was smaller by comparison.
When the prevalence of period- and cohort- obe-
sity were added as fixed covariates to the model
(Table 1,Model B), linear and quadratic age remained
significant (linear: β = 0.125, P< 0.001; quadratic:
β =−0.002, P< 0.001). Period-obesity (β = 6.101,
P< 0.001) and cohort-obesity (β = 4.582, P= 0.008)
were also significant fixed effects. The period effect
decreased (σ = 0.052, P= 0.038), but the cohort effect
did not change substantively (σ = 0.034, P= 0.028).
Similar results were observed when mean (Model C)
and median (Model D) BMI were included as fixed
covariates.
Models with 5-, 10-, and 15-year lag periods are
shown in Table 2. Themagnitude of period and cohort
effects were similar to that observed inmodels without
lag periods. However, the cohort effect decreased as
lag time increased, from 0.032 in the 5-year model
to 0.016 in the 15-year model. The period effect
decreased from 0.072 in the 10-year model to 0.035 in
the 15-year model.
DISCUSSION
The results of our study suggest the increasing inci-
dence of EAC is a complex function of age, time
period, and birth cohort. We observed that much
of the rise in incidence is driven by a period effect.
Others have similarly reported large increases in
incidence over time, with annual increases of 2–
8% since the 1970s.5,11 Our study extends the find-
ings of previous research by demonstrating that, not
only has incidence increased over time, but that the
increase is likely attributable to the growing preva-
lence of obesity. Many have hypothesized the increase
in incidence is related to trends in obesity preva-
lence because obesity is independently associated with
a risk of both EAC16 and Barrett’s esophagus.17,18
Although its role in EAC has been recognized for
many years, the extent to which trends in the preva-
lence of obesity might account for changes in inci-
dence has not been extensively studied. Incorporating
obesity as a fixed effect in our model allowed us
to quantify its contribution to changes in incidence
patterns.
Considerable evidence links obesity to EAC risk.
The relationship between obesity and EAC was first
reported in case-control studies in the 1990s, which
showed an elevated risk of cancer for the heaviest level
of BMI compared to normal weight.6,19–21 These find-
ings have since been validated by large, population-
based cohort studies22–24 that also suggest higher BMI
increases risk. To date, most research has focused on
the relationship between obesity and GERD as the
mechanical pathway linking BMI with EAC. Obe-
sity predisposes patients to reflux through a variety
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Table 2 Hierarchical Poisson model estimates of incidence rates of esophageal adenocarcinoma, including lag periods, of white males,
SEER, 1973–2012
Model
5-Year Time Lag* 10-Year Time Lag† 15-Year Time Lag‡
Fixed effects Coefficient SE P Coefficient SE P Coefficient SE P
Model for mean
Intercept − 12.254 0.364 <0.001 − 11.727 0.395 <0.001 − 11.072 0.353 <0.001
Age (linear, centered) 0.126 0.004 <0.001 0.126 0.003 <0.001 0.125 0.003 <0.001
Age (quadratic) − 0.002 <0.001 <0.001 − 0.002 <0.001 <0.001 − 0.002 <0.001 <0.001
Period obesity (%) 5.588 1.418 <0.001 4.929 1.741 0.005 3.812 1.655 0.021
Cohort obesity (%) 4.268 1.400 0.002 3.523 1.297 0.007 2.481 1.220 0.042
Variance Components Variance SE P Variance SE P Variance SE P
Period
Intercept 0.075 0.044 0.046 0.072 0.047 0.062 0.035 0.026 0.086
Cohort
Intercept 0.029 0.016 0.032 0.021 0.012 0.038 0.016 0.010 0.052
SE, standard error.
*Limited to incidence rates from SEER, 1975–2012.
†Limited to incidence rates from SEER, 1980–2012.
‡Limited to incidence rates from SEER, 1985–2012.
of mechanisms, including increased intra-abdominal
pressure, delayed gastric emptying, relaxation of the
lower esophageal sphincter, and loss of the angle of
His. These mechanisms are supported by the dose-
dependent relationship between BMI and GERD,
whereby the prevalence of GERD increases with
increasing levels of BMI.25,26 More recent evidence
suggests there may be an indirect metabolic effect
of abdominal obesity on risk of EAC.27,28 Although
the exact mechanism by which obesity affects EAC
pathogenesis has not been completely elucidated, sub-
stantial evidence provides support for the association
between obesity and EAC.
We also observed a birth cohort effect on incidence
patterns, which was not explained when obesity was
included as a fixed covariate in the model. Some have
suggested the decline in Helicobacter pylori coloniza-
tion, which is inversely associated with risk of EAC,29
has contributed to rises in incidence.30 The prevalence
of H. pylori in western countries has decreased in
the last 30 years, and several studies have shown that
much of this decrease is due to a birth cohort effect.31
There are many proposed mechanisms by which H.
pylori may decrease risk of EAC,30 but most have
examined the role of H. pylori in suppressing gastric
acid production and preventing damage to the distal
esophagus when reflux arises.32 Others have argued
that H. pylori only plays a minor role in the sharp
increase in incidence rates or is merely a maker of
some other risk factor (e.g. changes in microbiota).
Our study underscores the need for a better under-
standing of the critical factors involved with cohort-
mechanisms, includingH. pylori or microbiota, which
may be related to risk of EAC.
Our findings are similar to other APC studies
of EAC, both in the U.S. and Europe, which have
also shown independent period and cohort effects.
The methods used across these studies vary; many
use log-linear regression analysis,4,33–35 where coef-
ficients are constrained to be equal, while others
have developed multistage models that incorporate
features of the carcinogenic process in estimating
effects by age, period, and cohort.36–38 Despite dif-
ferent methodological approaches, the findings are
consistent and support the conclusions reached in
this study. Increases in incidence can be attributed to
both a period and cohort effect. Efforts to include
explanatory variables (e.g. symptomatic GERD, obe-
sity) in models, however, have had less consistent
results. Some research suggests trends in EAC inci-
dence do not match corresponding trends in lifestyle-
related risk factors, including obesity.37 Yet, a dif-
ferent study reports BMI is the predominant driver
of disease progression.38 Differences in our results
and those of others may be explained by differences
in model assumptions, measurement of explanatory
variables (e.g. self-reported BMI), and outcome (i.e.
absolute vs. relative increases in incidence).
There are several strengths of this study. We used a
new and innovative form of APC analysis, which has
not been previously applied to cancer incidence rates.
By developing a mixed effects model, we were able to
avoid the identification problem of linear APCmodels
and independently estimate the contribution of age,
period, and birth cohort to incidence rates. The mixed
effects model also allowed us to quantify the impact
of obesity on increasing incidence rates. Data for the
study were derived from two large, population-based
sources (SEER, NHANES), which have a similar age
and racial distribution of the entire U.S. population.
An important limitation of the models developed
for our study is that they are not models of etiology
and cannot provide information on the specific mech-
anism by which obesity is related to carcinogenesis.
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Our models do not distinguish between the many
factors that have led to increases in obesity prevalence
(e.g. diet, physical inactivity) that could also be related
to risk. There may be other etiologic factors or expo-
sures that cannot be accounted for in themodel, either
because their relationship with risk is still unknown or
the prevalence is not monitored in population-based
sources with sufficiently long follow-up. This limita-
tion highlights the importance of robust data sources
to fully understand the evolution of the disease over
time. There is also some evidence to suggest increases
in EAC predated SEER data,39 which may result in
an underestimate of the period effect. Finally, our
analysis was also limited to white men. Incidence of
EAC is lower in other race-sex groups, and there may
be different contributions of age, period, birth cohort,
and explanatory covariates in these population
subgroups.
EAC is one of the few cancers in the U.S. with a
rising incidence, and incidence is expected to increase
in the coming years. Our results tell an unambiguous
story regarding the role of obesity in EAC: changes in
incidence have been largely driven by increases in the
prevalence of obesity over time.Althoughwe observed
a small cohort effect, the magnitude of the period
effect and contribution of obesity was much larger
by comparison. This has important implications for
when and where to intervene along the EAC con-
tinuum. Specifically, efforts related to the prevention
of EAC may be best spent reducing the prevalence of
obesity. Given the low absolute risk of EAC in the gen-
eral population, it may be worth considering whether
directing obesity prevention at populations with an
increased risk profile, including obese persons with
GERD or Barrett’s esophagus, is appropriate in pre-
venting EAC. Causal mechanisms and pathways by
which obesity increases cancer risk are still debated,
but targeting efforts at weight reduction to these high
risk groups may be an effective strategy to reduce the
burden of EAC.
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